Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial
Academic Article
Publication Date:
2020
Abstract:
Istaroxime is a first-in-class agent which acts through inhibition of the sarcolemmal Na+ /K+ pump and activation of the SERCA2a pump. This study assessed the effects of a 24 h infusion of istaroxime in patients hospitalised for acute heart failure (AHF).
CRIS type:
1.1 Articolo in rivista
Keywords:
Acute heart failure; Istaroxime; Outcomes; SERCA2a; Therapy
List of contributors:
Carubelli, Valentina; Zhang, Yuhui; Metra, Marco; Lombardi, Carlo; Felker, G Michael; Filippatos, Gerasimos; O'Connor, Christopher M; Teerlink, John R; Simmons, Phillip; Segal, Robert; Malfatto, Gabriella; La Rovere, Maria Teresa; Li, Dianfu; Han, Xiumin; Yuan, Zuyi; Yao, Yali; Li, Benjamin; Lau, Lit Fui; Bianchi, Giuseppe; Zhang, Jian
Published in: